This handy credit card sized leaflet gives basic information on prostate cancer and other prostate problems, including information on risk factors and symptoms. These cards are ideal for displays and events. Suitable for health professionals and organisations to help promote prostate cancer awareness. Winner of the 2014 Pocket Media Awards.

Last updated: January 2017
To be reviewed: June 2019


  • Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. NHS Cancer Screening Programmes, 2009.
  • Colin SM, Metcalfe C, Donovan J, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen detected localized and advanced prostate cancer: a case-control study nested within the UK based population ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008;102(10):1400-40.
  • Crawford E D. Understanding the Epidemiology, Natural History and Key Pathways Involved in Prostate Cancer. 2009 Urology;73:5A
  • Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-94.
  • Kirby M, Chapple C, Jackson G, et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract 2013;67(7):606-18.
  • Lifetime risk of cancer. Cancer Research UK. 2010. Available
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med 2015;13(1):171
  • Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology. April 2014
  • Popiolek M, Rider JR, Andren O, et al. Natural history of early, localized prostate cancer: A final report from three decades of follow-up. Eur Urol 2013;63(3):428-35.
  • Prostate cancer incidence statistics. Cancer Research UK. 2011. Available from:
  • Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. Evidence document January 2010.
  • Prostate cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence (NICE). January 2014. Clinical guideline 175.
  • Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101(3):17-21.
  • Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol 2013;64(6):981–87.
  • Speakman M, Kirby R, Doyle S, Loannau C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK. BJU Int 2014
  • Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2012;110(7):1014–22.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.